Related Experiment Video
Updated: Aug 5, 2026
12:22
The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
DCC protein expression in clear cell renal cell carcinoma
1Department of Urology, Rabin Medical Center-Beilinson Campus, Petah Tikva, Israel. yoramdekel@hotmail.com
BJU International
|March 31, 2004
Summary
Under-expression of Deleted in Colorectal Cancer (DCC) protein indicates aggressive renal cell carcinoma (RCC) and higher mortality risk. Further studies are needed to confirm these findings in a larger patient cohort.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- The Deleted in Colorectal Cancer (DCC) gene is a known prognostic factor in colorectal carcinoma, predicting poor patient outcomes.
- Investigating novel prognostic markers is crucial for improving patient management in renal cell carcinoma (RCC).
Purpose of the Study:
- To determine if Deleted in Colorectal Cancer (DCC) protein expression can serve as a prognostic factor in renal cell carcinoma (RCC).
- To correlate DCC protein expression levels with tumour behaviour and patient survival in RCC.
Main Methods:
- Immunohistochemical analysis of DCC protein expression in 94 clear cell RCC tumour samples (stages T1-T3).
- Patient follow-up averaged 52.3 months, with endpoints including disease recurrence and death.
- Statistical analysis to correlate DCC expression with clinicopathological features and outcomes.
Main Results:
- DCC protein under-expression was observed in 63% of patients who died from RCC, versus 36% of those with no evidence of disease.
- Under-expression was noted in all T1 stage RCC patients who died from the disease, 50% of T2, and 67% of T3.
- A significant correlation was found between DCC protein under-expression and aggressive tumour characteristics.
Conclusions:
- DCC protein under-expression is associated with more aggressive tumour behaviour and an increased risk of mortality in renal cell carcinoma.
- These findings suggest DCC may be a potential prognostic biomarker for RCC.
- Larger cohort studies are recommended to validate these preliminary conclusions and establish definitive prognostic value.
